Sale

Interleukin Inhibitors Market

Global Interleukin Inhibitors Market Size, Share, Forecast: By Type: L-17, IL-23, IL-1, IL-5, IL-6, Others; By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Others; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; 2024-2032

Global Interleukin Inhibitors Market Outlook

The global interleukin inhibitors market is expected to grow over the forecast period 2024-2032, growing at a CAGR of 13.5%. The interleukin inhibitors market is driven by the highly effective work of interleukin inhibitors in treating autoimmune disease.

 

Interleukin Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

Interleukin inhibitors are referred to as the immunosuppressive agents, which limit the activity of interleukins. Interleukin is a group of cytokines that are synthesized by lymphocytes, macrophages, monocytes, and certain other cells. Their role is to regulate the immune system.

 

Interleukin Inhibitors Market by Application

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The interleukin inhibitors market is segmented based on types and applications.

Based on type, the interleukin inhibitors market is divided into:

  • L-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Others

Based on application, the interleukin inhibitors market is segmented into:

The EMR report looks into the regional interleukin inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Interleukin Inhibitors Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The global interleukin inhibitors market is being driven by the highly effective work of interleukin inhibitors in treating autoimmune disease. The interleukin inhibitors market is aided by the numerous approved interleukin inhibitor molecules for treating autoimmune conditions like rheumatoid arthritis, psoriasis, and Crohn’s disease. Moreover, R&D is in progress over interleukin inhibitor molecules, and clinical trials for late-stage molecules is expected to impact market growth positively. Higher patient adherence to these drugs due to their higher affinity and specificity, as compared to other conventional approved autoimmune therapeutics, is predicted to increase their sales.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global interleukin inhibitors market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Novartis AG 
  • AbbVie Inc 
  • Eli Lilly and Company 
  • Regeneron Pharmaceuticals, Inc. 
  • Johnson & Johnson Services, Inc 
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca 
  • Bausch Health 
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Industries, Ltd. 
  • Others

The EMR report gives an in-depth insight into the interleukin inhibitors market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Application
  • Region
Breakup by Type
  • L-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Others
Breakup by Application
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Asthma
  • Inflammatory Bowel Disease
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Novartis AG 
  • AbbVie Inc 
  • Eli Lilly and Company 
  • Regeneron Pharmaceuticals, Inc. 
  • Johnson and Johnson Services, Inc. 
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca 
  • Bausch Health 
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Industries, Ltd. 
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Interleukin Inhibitors Market Analysis
    8.1    Key Industry Highlights
    8.2    Global Interleukin Inhibitors Historical Market (2018-2023) 
    8.3    Global Interleukin Inhibitors Market Forecast (2024-2032)
    8.4    Global Interleukin Inhibitors Market by Type
        8.4.1    L-17
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    IL-23
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    IL-1
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    IL-5
            8.4.4.1    Historical Trend (2018-2023)
            8.4.4.2    Forecast Trend (2024-2032)
        8.4.5    IL-6
            8.4.5.1    Historical Trend (2018-2023)
            8.4.5.2    Forecast Trend (2024-2032)
        8.4.6    Others
    8.5    Global Interleukin Inhibitors Market by Application
        8.5.1    Psoriasis
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Psoriatic Arthritis
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Rheumatoid Arthritis
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Asthma 
            8.5.4.1    Historical Trend (2018-2023)
            8.5.4.2    Forecast Trend (2024-2032)
        8.5.5    Inflammatory Bowel Disease 
            8.5.5.1    Historical Trend (2018-2023)
            8.5.5.2    Forecast Trend (2024-2032)
        8.5.6    Others
    8.6    Global Interleukin Inhibitors Market by Region       
        8.6.1    North America
            8.6.1.1    Historical Trend (2018-2023) 
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Europe
            8.6.2.1    Historical Trend (2018-2023) 
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Asia Pacific
            8.6.3.1    Historical Trend (2018-2023) 
            8.6.3.2    Forecast Trend (2024-2032)
        8.6.4    Latin America
            8.6.4.1    Historical Trend (2018-2023) 
            8.6.4.2    Forecast Trend (2024-2032)
        8.6.5    Middle East and Africa
            8.6.5.1    Historical Trend (2018-2023) 
            8.6.5.2    Forecast Trend (2024-2032) 
9    North America Interleukin Inhibitors Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Interleukin Inhibitors Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Interleukin Inhibitors Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Interleukin Inhibitors Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Interleukin Inhibitors Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    Novartis AG
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    AbbVie Inc.
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Eli Lilly and Company
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Regeneron Pharmaceuticals, Inc.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    Johnson and Johnson Services, Inc.
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    F. Hoffmann-La Roche Ltd.
            16.2.6.1    Company Overview
            16.2.6.2    Product Portfolio
            16.2.6.3    Demographic Reach and Achievements
            16.2.6.4    Certifications
        16.2.7    AstraZeneca
            16.2.7.1    Company Overview
            16.2.7.2    Product Portfolio
            16.2.7.3    Demographic Reach and Achievements
            16.2.7.4    Certifications
        16.2.8    Bausch Health
            16.2.8.1    Company Overview
            16.2.8.2    Product Portfolio
            16.2.8.3    Demographic Reach and Achievements
            16.2.8.4    Certifications
        16.2.9    GlaxoSmithKline plc
            16.2.9.1    Company Overview
            16.2.9.2    Product Portfolio
            16.2.9.3    Demographic Reach and Achievements
            16.2.9.4    Certifications
        16.2.10    Teva Pharmaceuticals Industries, Ltd.
            16.2.10.1    Company Overview
            16.2.10.2    Product Portfolio
            16.2.10.3    Demographic Reach and Achievements
            16.2.10.4    Certifications
        16.2.11    Others
17    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Interleukin Inhibitors Market: Key Industry Highlights, 2018 and 2032
2.    Global Interleukin Inhibitors Historical Market: Breakup by Type (USD Million), 2018-2023
3.    Global Interleukin Inhibitors Market Forecast: Breakup by Type (USD Million), 2024-2032
4.    Global Interleukin Inhibitors Historical Market: Breakup by Application (USD Million), 2018-2023
5.    Global Interleukin Inhibitors Market Forecast: Breakup by Application (USD Million), 2024-2032
6.    Global Interleukin Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2023
7.    Global Interleukin Inhibitors Market Forecast: Breakup by Region (USD Million), 2024-2032
8.    North America Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
9.    North America Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
10.    Europe Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
11.    Europe Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Asia Pacific Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Asia Pacific Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Latin America Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Latin America Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Middle East and Africa Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
17.    Middle East and Africa Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Global Interleukin Inhibitors Market Structure

Key Questions Answered in the Report

The global interleukin inhibitors market is projected to grow at a CAGR of 13.5% between 2024 and 2032.

The major drivers of the market include the research and development activities, rise in awareness amongst the consumers and physicians, rise in the prevalence of chronic inflammatory diseases such as psoriasis, arthritis, rise in FDA approvals for novel drugs and therapies, increase in the prevalence of autoimmune diseases, and high adoption of advanced treatment options.

The highly effective work of interleukin inhibitors in treating autoimmune diseases and higher patient adherence are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on type, the interleukin inhibitors market is divided into L-17, IL-23, IL-1, IL-5, and IL-6, among others.

The major applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease, among others.

The major players in the industry are Novartis AG, AbbVie Inc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca, Bausch Health, GlaxoSmithKline plc, and Teva Pharmaceuticals Industries, Ltd., among others.

Analyst Review

The global interleukin inhibitors market has been driven by the highly effective work of interleukin inhibitors in treating autoimmune diseases in the historical period. Aided by the rise in awareness amongst the consumers and physicians and rise in the prevalence of chronic inflammatory diseases, the market is expected to witness further growth in the forecast period of 2024-2032, growing at a CAGR of 13.5%.

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the interleukin inhibitors market is divided into L-17, IL-23, IL-1, IL-5, and IL-6, among others. The major applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease, among others. The major regional markets for the interleukin inhibitors market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The major players in the industry are Novartis AG, AbbVie Inc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca, Bausch Health, GlaxoSmithKline plc, and Teva Pharmaceuticals Industries, Ltd., among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER